+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Differential Sensitivity of Growth Hormone-Releasing Hormone and Somatostatin Release from Perifused Mouse Hypothalamic Fragments in Response to Glucose Deficiency

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          The effects of glucose deficiency on growth hormone (GH)-releasing hormone (GRH) and somatostatin (SRIH) release from mouse hypothalamic fragments were investigated using an in vitro perifusion system. Fragments were perifused with Krebs-Ringer bicarbonate solution (KRB) containing 5.6 m M glucose for 3 h followed by reduced glucose concentrations in KRB for the next 2 h. GRH release was simulated by 0.7-2.8 m M glucose in an inverse concentration-dependent manner. In contrast, SRIH release was not stimulated by glucose at concentrations of 2.8 and 1.4 m M; only at 0.7 m M was there a modest stimulation of SRIH release that was comparable to the effect of 2.8 m M glucose on GRH release. The maximal stimulation of GRH and SRIH release by 0.7 m M glucose was 221 and 150%, respectively, of controls. Glucose concentrations of 11.2 and 22.4 m M inhibited GRH release but did not alter SRIH release. The glucose analog 2-deoxy-D-glucose (2-DG; 5.6-39.2 m M) also stimulated GRH release in a dose-dependent manner, and SRIH release was less sensitive to 2-DG than was GRH. The maximal stimulation of GRH and SRIH release by 39.2 mM2-DG was 190 and 147%, respectively, of controls. Increases in GRH and SRIH release stimulated by 30 m M KC1 1 h after exposure to low glucose or 2-DG were not significantly different from those after exposure to 5.6 m M glucose. However, the SRIH response to K<sup>+</sup>-induced depolarization was much greater than that of GRH. The glucose intermediate pyruvate (4.9 and 9.8 m M) partially inhibited both GRH and SRIH release induced by 0.7 m M glucose. The glutamate receptor antagonist 2-amino-7-phosphonoheptanoic acid also partially inhibited the GRH release induced by 0.7 m M glucose. These results indicate that mouse hypothlaamic GRH release is more sensitive to the inhibition of intracellular glycolysis than is SRIH release. Although inhibition of glycolysis appears to mediate glucopenia-induced GRH and SRIH release, the predominance of GRH release cannot be explained by nonspecific membrane depolarization subsequent to energy reduction. An additional mechanism involved in the specific release of GRH induced by glucose deficiency may relate to activation of endogenous glutamate receptor activity.

          Related collections

          Author and article information

          S. Karger AG
          08 April 2008
          : 57
          : 6
          : 1097-1105
          Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA
          126476 Neuroendocrinology 1993;57:1097–1105
          © 1992 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 9
          Original Paper


          Comment on this article